Mihoko Kai, Ph.D.

Dr. Mihoko Kai manages a portfolio of grants focusing on tumor heterogeneity, stem cell biology, non-coding RNAs in the tumor microenvironment, and hormone signaling.  

Along with her DCB responsibilities, Dr. Kai is also a member of the Non-Endometrioid Uterine Cancer Working Group. 

In addition to her portfolio, Dr. Kai's scientific interests include understanding associations between the aging process and cancer, as well as the development of  better model systems for tumor microenvironment research. She says, “The improvements in single-cell RNA sequencing, genomic studies, and model systems have given us the ability to further understand new phenomenon in cancer."     

Research Programs

Dr. Kai also helps manage NCI cooperative agreement programs: 

• Translational and Basic Science in Early Lesions (TBEL)
• Acquired Resistance to Therapy Network (ARTNet)

Background

Before coming to DCB, Dr. Mihoko was a principal investigator at Johns Hopkins School of Medicine. She values the opportunities that DCB provides for bridging the gap between the basic and translational science research, as well as the opportunity to support research focusing on various tumor types.